| Accent Resources N.L. (ACS) ORDINARY FULLY PAID |
Materials |
$19 |
Jun25 Appendix 5B Quarterly Cashflow Report
|
29 Jul 2025 10:11AM |
$0.008 |
$0.038 |
risen by
375%
|
|
ACS - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers the period ending 31 May 2010.
- Details cash flows for operating, investing, and financing activities.
- Payments for exploration and evaluation constituted a major cash outflow.
- Administration and corporate costs are itemized.
- The report discloses no receipts from customers for the quarter.
- There were no significant acquisitions or disposals of tenements.
- Cash at the beginning and end of the period is reported.
- Information on loans, equity, and other forms of financing is included.
- Directors confirm the report's compliance with accounting standards.
- Related party transactions and payments to directors are disclosed.
- Tenement interests held, acquired, or relinquished are listed.
- Options on issue and changes in securities during the quarter are provided.
- The company emphasizes prudent expenditure and governance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EQ Resources Limited (EQR) ORDINARY FULLY PAID |
Materials |
$1,244 |
Saloro Secures US$7.5m Royalty Funding
|
29 Jul 2025 10:08AM |
$0.037 |
$0.245 |
risen by
571.23%
|
|
EQR - Price-sensitive ASX Announcement
Full Release
Key Points
- Saloro S.L.U., a subsidiary of EQR, has secured a US$7.5 million royalty funding with Tangent Capital.
- Funding will accelerate development and production at the Barruecopardo Tungsten Mine in Spain.
- The agreement involves a royalty on tungsten concentrate sales, not equity in EQR.
- No equity dilution to EQR’s existing shareholders is expected from this funding.
- The Barruecopardo Mine is a key strategic asset in EQR’s portfolio.
- Funds will also support mine ramp-up and ongoing exploration activities.
- The deal strengthens EQR’s financial position and supports its growth trajectory.
- Tungsten is recognized as a critical mineral in Europe and globally.
- The arrangement aligns with EQR’s strategy to consolidate its position in the European critical minerals market.
- Announcement includes key agreement terms, benefits for EQR, and relevance to critical minerals supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Manuka Resources Ltd (MKR) ORDINARY FULLY PAID |
Materials |
$143 |
Maiden Mt Boppy Open Pit Ore Reserve
|
29 Jul 2025 10:02AM |
$0.048 |
$0.090 |
risen by
87.50%
|
|
MKR - Price-sensitive ASX Announcement
Full Release
Key Points
- Manuka Resources Ltd (MKR) announces a Maiden Mt Boppy Open Pit Ore Reserve.
- The Ore Reserve is underpinned by updated Mineral Resource and pit design work.
- Key modifying factors include mining dilution, ore loss, and processing recoveries.
- The project is located in New South Wales and has strategic value for MKR.
- The Reserve provides potential for near-term gold production.
- Extensive geological, metallurgical, and economic studies support the estimate.
- The announcement details Reserve tonnage, grade, and gold ounces.
- Positive implications for MKR’s future production and shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mithril Silver and Gold Limited (MTH) ORDINARY FULLY PAID |
Materials |
$56 |
High-Grade Channel Sampling Results
|
29 Jul 2025 10:02AM |
$0.485 |
$0.300 |
fallen by
38.14%
|
|
MTH - Price-sensitive ASX Announcement
Full Release
Key Points
- Mithril Silver and Gold Limited (MTH) announced high-grade channel sampling results at the Copalquin district in Mexico.
- Channel sampling at the El Refugio area returned significant gold and silver grades.
- Results highlight the presence of high-grade mineralised structures at surface.
- Notable channel sample intercepts include substantial gold and silver values.
- Results support the potential for near-surface resource expansion.
- The findings confirm the district's prospectivity for further exploration.
- Mithril plans additional work to expand and further define mineralised zones.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strategic Energy Resources Limited (SER) ORDINARY FULLY PAID |
Materials |
$8 |
Investor Presentation
|
29 Jul 2025 10:01AM |
$0.007 |
$0.135 |
risen by
1,828.57%
|
|
| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$106 |
Proposed issue of securities - RML
|
29 Jul 2025 10:01AM |
$0.087 |
$0.048 |
fallen by
45.40%
|
|
| Ausminerals Limited (AUE2) ORDINARY FULLY PAID |
Materials |
- |
Encouraging Drilling Results at BD & BST
|
29 Jul 2025 10:00AM |
n/a |
n/a |
n/a
|
|
| Narryer Metals Limited (NYM) ORDINARY FULLY PAID |
Materials |
$12 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jul 2025 9:57AM |
$0.040 |
$0.058 |
risen by
45%
|
|
NYM - Price-sensitive ASX Announcement
Full Release
Key Points
- Exploration focused on critical minerals including REE, lithium, and nickel.
- Significant activity at Rocky Gully, Ceduna, Sturt, and Mt James projects.
- New tenement applications and ongoing project generation.
- Positive assay results, particularly at Ceduna and Rocky Gully.
- No production or sales recorded in the quarter.
- Operating cash outflows primarily related to exploration activities.
- Closing cash balance of $2.6 million as of 31 December 2023.
- Minimal payments to related parties, limited to director fees.
- Company is well-funded to continue exploration strategy.
- Focus remains on advancing critical minerals projects for global demand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beonic Ltd (BEO) ORDINARY FULLY PAID |
Information Technology |
$5 |
Seven Airport Contract with North African Airport Authority
|
29 Jul 2025 9:57AM |
$0.215 |
$0.076 |
fallen by
64.65%
|
|
BEO - Price-sensitive ASX Announcement
Full Release
Key Points
- Beonic Ltd (formerly BEO) secured a contract with a North African Airport Authority.
- The contract covers the supply, installation, and commissioning of airport management and control systems.
- Seven airports in North Africa are included in the scope of the contract.
- The contract value exceeds $10 million.
- Beonic will provide integrated airport management software, flight information display, security systems, and communications infrastructure.
- Beonic is responsible for project management, engineering, installation, and after-sales support.
- This contract signifies Beonic’s expansion into international airport technology markets.
- The deal will have a significant positive impact on Beonic’s revenue and market profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Artemis Resources Limited (ARV) ORDINARY FULLY PAID |
Materials |
$15 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jul 2025 9:57AM |
$0.006 |
$0.004 |
fallen by
27.27%
|
|
ARV - Price-sensitive ASX Announcement
Full Release
Key Points
- Artemis Resources Limited released its quarterly activities and cash flow report for the period ending 31 December 2023.
- Exploration focused on the Karratha Gold Project and Paterson Central Project, with drilling and surveys at multiple targets.
- The company reviewed its Pilbara non-core projects for potential strategic options.
- Operational expenditure and cash burn are detailed in the Appendix 5B cash flow report.
- Artemis ended the quarter with a specified cash balance, demonstrating prudent financial management.
- The company remains dedicated to advancing its Western Australian gold and base metal assets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ASX Limited (ASX) ORDINARY FULLY PAID |
Financials |
$9,753 |
Webcast Details and Key Dates for 2025 Full-Year Results
|
29 Jul 2025 9:57AM |
$70.210 |
$49.910 |
fallen by
28.91%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$56 |
Notice under Section 708A(5)(e) of the Corporations Act
|
29 Jul 2025 9:55AM |
$0.240 |
$0.110 |
fallen by
54.17%
|
|
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$71 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 9:55AM |
$0.022 |
$0.020 |
fallen by
9.09%
|
|
RAD - Price-sensitive ASX Announcement
Full Release
Key Points
- Radiopharm Theranostics Limited (RAD) provided an update on its activities for the quarter ended 31 March 2024.
- The company made significant progress across its clinical development pipeline, including Phase I and Phase II trials for its radiopharmaceutical products.
- RAD received regulatory and ethics approvals for its Phase I clinical trial of RAD 301 in the US for treatment of patients with advanced solid tumors.
- The company's Phase I trial of RAD 204 (Nano-mAbs) for HER2-positive breast cancer commenced recruitment.
- RAD reported the initiation of a preclinical research collaboration with leading academic and clinical partners.
- A collaboration with MD Anderson Cancer Center for the development of novel radiopharmaceuticals was highlighted.
- RAD continued to advance its global intellectual property portfolio, filing new patents.
- The company reported operating cash outflows of approximately $5.2 million during the quarter.
- RAD had a cash balance of $26.9 million at the end of the reporting period, positioning it well to fund ongoing clinical trials and research.
- No payments were made to related parties or their associates other than director fees and reimbursement of expenses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$77 |
Prescient announces results of SPP & Launches Placement
|
29 Jul 2025 9:54AM |
$0.045 |
$0.073 |
risen by
62.22%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient Therapeutics Limited completed a Share Purchase Plan (SPP) raising approximately $2.7 million.
- A new placement is launched aiming to raise a further $5 million at the same issue price as the SPP.
- Funds raised will support the advancement of the OmniCAR and CellPryme cancer therapy platforms.
- The capital will also be used for general working capital requirements.
- Shareholders were thanked for their continued support.
- The company outlined its strategy to progress both financial and research objectives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$106 |
Resolution to Pursue NASDAQ Listing
|
29 Jul 2025 9:53AM |
$0.079 |
$0.048 |
fallen by
39.87%
|
|
RML - Price-sensitive ASX Announcement
Full Release
Key Points
- Resolution Minerals Ltd intends to pursue a listing on the NASDAQ stock exchange.
- The decision aims to access deeper capital markets and attract North American investors.
- NASDAQ is viewed as providing greater access to capital for mineral exploration companies.
- The company will maintain its existing ASX listing alongside the proposed NASDAQ listing.
- The dual listing is expected to increase visibility, liquidity, and access to funding.
- The process involves meeting NASDAQ's listing requirements and regulatory approvals.
- Shareholder engagement and communication remain a priority during the transition.
- The move supports Resolution Minerals' strategy for growth and exploration activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Diatreme Resources Limited (DRX) ORDINARY FULLY PAID |
Materials |
$65 |
Diatreme signs negotiation protocol with Gulaal People
|
29 Jul 2025 9:52AM |
$0.018 |
$0.013 |
fallen by
27.78%
|
|
DRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Diatreme Resources Limited has signed a negotiation protocol with the Gulaal People.
- The Gulaal People are the native title claimants for the Cape Bedford Silica Sand Project area.
- The protocol provides a framework for respectful engagement and negotiation.
- The agreement aims to support both project advancement and Gulaal People interests.
- This milestone enhances Diatreme’s commitment to working collaboratively with traditional owners.
- The negotiation process will address cultural, social, and economic considerations.
- Formal agreement is the intended outcome of the protocol to enable project development.
- Diatreme recognises the importance of ensuring free, prior, and informed consent from traditional owners.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Activex Limited (AIV) ORDINARY FULLY PAID |
Materials |
$7 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jul 2025 9:52AM |
$0.016 |
$0.023 |
risen by
43.75%
|
|
AIV - Price-sensitive ASX Announcement
Full Release
Key Points
- Activex Limited (AIV) released its Quarterly Activities Report and Appendix 5B Cash Flow Report for the quarter ended 31 March 2024.
- The company made significant progress on the Florence Lake and Horseshoe West nickel exploration projects in Western Australia.
- Florence Lake drilling identified high-grade nickel sulphide, with notable intersections and successful downhole electromagnetic surveys completed.
- Horseshoe West drilling program commenced, with initial results confirming key geological features and encouraging follow-up exploration.
- Corporate activities included completion of a share placement raising $1.3 million before costs, and the appointment of a new Non-Executive Director.
- Cash outflows were primarily related to exploration and evaluation activities, with $1.1 million spent during the quarter.
- As of 31 March 2024, Activex reported a cash balance of $2.6 million.
- No mining production or development activities occurred during the quarter.
- The Appendix 5B report detailed exploration, staff, administration, and fundraising expenditure, with no payments to related parties during the reporting period.
- The company remains focused on advancing its nickel projects and maintaining a strong liquidity position for ongoing exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sequoia Financial Group Ltd (SEQ) ORDINARY FULLY PAID |
Financials |
$16 |
Pause in Trading
|
29 Jul 2025 9:51AM |
$0.240 |
$0.130 |
fallen by
45.83%
|
|
SEQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Sequoia Financial Group Ltd requested a trading halt on its securities.
- The trading halt is effective from 3 June 2024.
- The pause is pending an announcement about a material transaction.
- The halt may last until the announcement or until 5 June 2024.
- The company is not aware of any reason why the trading halt should not be granted.
- No additional market-sensitive information is being withheld.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$679 |
Geoff Wilson Appendix 3Y
|
29 Jul 2025 9:50AM |
$1.550 |
$1.690 |
risen by
9.03%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$56 |
Application for quotation of securities - ATX
|
29 Jul 2025 9:50AM |
$0.240 |
$0.110 |
fallen by
54.17%
|
|
| Liontown Limited (LTR) ORDINARY FULLY PAID |
Materials |
$7,264 |
June 2025 Quarter Presentation
|
29 Jul 2025 9:49AM |
$0.865 |
$2.285 |
risen by
164.16%
|
|
LTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Produced over 294,000 dmt of spodumene concentrate in FY25.
- Achieved A$112M in cost savings and deferrals, exceeding target.
- Maintained a strong cash balance of A$156M as of June 2025.
- Initiated underground production, with full transition planned by Q3 FY26.
- Aimed for a 70% lithia recovery target by Q3 FY26.
- Adapted to a 36% fall in spodumene prices over 12 months.
- Secured A$300M debt facility from Ford and US$250M convertible note from LG Energy Solution.
- Planned for scalable operations, with focus on low-cost production from FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Liontown Limited (LTR) ORDINARY FULLY PAID |
Materials |
$7,264 |
June 2025 Quarter Presentation
|
29 Jul 2025 9:49AM |
$0.865 |
$2.285 |
risen by
164.16%
|
|
LTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Commencement of underground production on schedule.
- Robust cash balance of A$156M at 30 June 2025.
- A$112M in cost savings and deferrals achieved in FY25.
- Transition to 100% underground production by Q3 FY26 planned.
- 70% lithia recovery target by Q3 FY26 remains unchanged.
- Over 294,000 dmt concentrate produced in FY25.
- Strategic focus on optimizing mining and processing schedules.
- Deployment of technology to improve plant performance.
- Preparation for low-cost, scalable operations expected from FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 9:49AM |
$0.018 |
$0.017 |
fallen by
8.33%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomo Diagnostics Limited provided a detailed update for the quarter ending 31 December 2023.
- The AT1 HIV Self-Test remains a core focus, with advances in regulatory submissions and market launches, especially in Europe and Australia.
- The company engaged in partnership discussions and collaborations to expand product reach and access.
- Operational highlights include notable supply agreements and new distribution partnerships.
- Research and development activities are ongoing, with attention to product pipeline and innovation.
- Financially, Atomo reported receipts from customers, operating costs, and overall cash position in the Appendix 4C.
- The company continues to seek opportunities for market expansion and sustained financial performance.
- The report demonstrates Atomo's commitment to regulatory compliance, commercial growth, and maintaining adequate funding for its operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Unico Silver Limited (USL) ORDINARY FULLY PAID |
Materials |
$436 |
Former De Grey CFO to be appointed to Unico Board
|
29 Jul 2025 9:48AM |
$0.440 |
$0.688 |
risen by
56.25%
|
|
| Eureka Group Holdings Limited (EGH) ORDINARY FULLY PAID |
Real Estate |
$262 |
Change in substantial holding
|
29 Jul 2025 9:48AM |
$0.560 |
$0.610 |
risen by
8.93%
|
|
Call 1300 880 160
Start a chat
Schedule a call
